中泰国际每日晨讯-20251023

Market Performance - The Hang Seng Index closed at 25,782 points, down 0.94%, while the Hang Seng China Enterprises Index fell 0.85% to 9,224 points[1] - Total turnover in Hong Kong stocks was HKD 227.5 billion, lower than HKD 264.7 billion on Tuesday, indicating market caution[1] - Energy sector rose by 0.3%, while non-essential consumer goods, healthcare, information technology, and conglomerates fell by 1.3%, 1.9%, 1.1%, and 1.2% respectively[1] Stock Highlights - China National Pharmaceutical (1099 HK) and Pop Mart (9992 HK) led the gainers, rising by 4.3% and 2.4% respectively[1] - Chow Tai Fook (1929 HK) and CSPC Pharmaceutical (1093 HK) were the biggest losers, dropping by 5.7% and 5.2% respectively[1] Commodity Trends - Gold prices fell below USD 4,100, with mining and retail stocks in Hong Kong following suit[1] - Zijin Mining (2899 HK), Zhaojin Mining (1818 HK), Chow Tai Fook (1929 HK), and Lao Poo Gold (6181 HK) saw declines between 1.7% and 8.2%[1] Economic Indicators - U.S. mortgage applications decreased by 0.3% for the week ending October 17, better than the previous week's decline of 1.8%[3] - U.S. crude oil inventories fell by 960,000 barrels, contrary to market expectations of a 1.2 million barrel increase[3] - UK inflation rate for September remained at 3.8%, below the market forecast of 4.0%[3] Corporate Developments - Lao Poo Gold (6181 HK) announced a placement of 3.71 million new shares, raising HKD 2.71 billion at a 4.5% discount to the previous closing price[4] - Pop Mart (9992 HK) reported strong overseas market performance in Q3, leading to a 2.4% increase in stock price[4] Pharmaceutical Sector - Innovent Biologics (1801 HK) entered a licensing agreement with Takeda Pharmaceutical for several therapies, receiving an upfront payment of USD 1.2 billion[5] - The strategic investment price of HKD 112.56 per share represents a 20% premium over the weighted average closing price prior to the agreement[5]